What is Vimta Labs Ltd (VIMTALABS) share price return in the past 10 years?

Vimta Labs Ltd share price has appreciated 30.5% annually (CAGR) over the past ten years.

What is the share price of Vimta Labs Ltd (VIMTALABS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Vimta Labs Ltd (VIMTALABS) on 05-Jun-2026 10:31:00 at 10:31 is 513.00.

What is the P/E ratio of Vimta Labs?

The latest standalone P/E ratio of Vimta Labs as of 05-Jun-2026 is 29.49.

What is the P/B ratio of Vimta Labs Ltd (VIMTALABS)?

The latest standalone P/B ratio of Vimta Labs Ltd (VIMTALABS) as of 05-Jun-2026 is 5.08.

What is the 52-week high and low of Vimta Labs Ltd (VIMTALABS)?

The 52-week high of Vimta Labs Ltd (VIMTALABS) is Rs. 902.85 and the 52-week low is Rs. 377.30.

Vimta Labs Ltd (VIMTALABS) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Vimta Labs Ltd (VIMTALABS)
Brand: Vimta Labs

Vimta Labs Ltd (VIMTALABS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524394 NSE: VIMTALABS Business Support | Small Cap | Vimta Labs Share Price

Vimta Labs Ltd (VIMTALABS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524394 NSE: VIMTALABS Business Support | Small Cap | Vimta Labs Share Price

Key Metrics

Valuation Multiples

Market Cap

₹2,286 Cr.

Current Price

₹513

52-Week Low / High

₹377 / 903

TTM EPS

₹17.4

TTM Sales

₹407 Cr.

Book Value per Share

₹100.6

P/E Ratio

29.49

Higher than its 5-year historical median

Industry PE

Price to Book (P/B)

5.08

Higher than its 5-year historical median

Price to Sales (P/S)

5.61

Higher than its 5-year historical median

EV/EBITDA

14.78

Higher than its 5-year historical median

Dividend Yield

0.53%

Profitability Efficiency

Return on Equity (ROE)

18.87%

Outperforms industry median

Return on Capital Employed (ROCE)

24.81%

Outperforms industry median

Return on Assets (ROA)

15.25%

Operating Profit Margin

34.8%

Net Profit Margin

19.03%

Gross Profit Margin

36.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

18.41%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

16.05%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

16.1%

Asset Quality

Promoter Holding

35.85%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹441 Cr.

Equity

₹8.9 Cr.

Face Value

₹2

All Time Low / High

₹0.10 / 902.85

Vimta Labs stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Vimta Labs Ltd a good quality company?

Vimta Labs Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Vimta Labs Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Vimta Labs Ltd vs industry peers?

Vimta Labs Ltd revenue CAGR is 13.74%, compared to the industry median CAGR of 0.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Vimta Labs Ltd?

Promoters hold 35.85% of the Vimta Labs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Vimta Labs Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 28.3% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	11.2%	16.6%	20.4%	6%	14.2%	23.9%	24.3%	20.6%	25.2%	24.8%	-
Value Creation Index ⓘ	-0.2	0.2	0.5	-0.6	0.0	0.7	0.7	0.5	0.8	0.8	-
Growth Parameters ⓘ
Sales ⓘ	154	183	213	181	209	276	315	289	344	407	407
Sales YoY Gr.	-	19.2%	15.9%	-15%	15.7%	32%	14.2%	-8.4%	19.2%	18.4%	-
Adj EPS ⓘ	2.5	3.8	5.6	1.3	4.9	9.5	10.5	10.9	14.9	17.1	17.4
YoY Gr.	-	52.2%	49.7%	-76.7%	272.5%	94.7%	10.4%	3.8%	36.9%	14.8%	-
BVPS (₹) ⓘ	30.8	34.4	38.8	39.1	43.9	52.2	62	69.3	83.7	100.6	100.6
Adj Net Profit ⓘ	10.9	16.6	24.9	5.8	21.6	42	46.5	48.3	66.3	76.4	77
Cash Flow from Ops. ⓘ	23.9	33.4	39.3	24.4	37	58.7	86.5	60.9	94.1	147	-
Debt/CF from Ops. ⓘ	1.8	1.2	0.7	1.3	0.8	0.3	0.2	0.3	0.1	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	11.4%	14.3%	8.9%	18.4%
Adj EPS ⓘ	24%	28.5%	17.7%	14.8%
BVPSⓘ	14.1%	18%	17.6%	20.3%
Share Price	30.5%	33.4%	35.5%	7.8%

Key Financial Parameters ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	8.3	11.5	15.4	3.4	11.7	19.6	18.1	16.2	19.1	18.3	17.2
Op. Profit Mgn % ⓘ	18.1	24.8	27.2	16.6	25.4	29	29.7	32.6	35.5	34.8	34.8
Net Profit Mgn % ⓘ	7.1	9.1	11.7	3.2	10.3	15.2	14.7	16.7	19.3	18.8	19
Debt to Equity ⓘ	0.3	0.3	0.2	0.2	0.2	0.1	0.1	0.1	0	0	0
Working Cap Days ⓘ	187	168	158	195	186	158	148	169	157	146	93
Cash Conv. Cycle ⓘ	99	92	101	128	113	95	92	115	114	105	66

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	154	183	213	181	209	276	315	289	344	407
Operating Expenses ⓘ +	127	138	155	151	156	196	222	195	222	266
Manufacturing Costs	59	59	68	63	68	90	87	71	86	101
Material Costs	0	2	-1	0	3	0	0	0	0	0
Employee Cost	43	49	55	58	57	71	86	85	91	105
Other Costs ⓘ	24	28	33	29	28	36	49	38	45	60
Operating Profit ⓘ	27	45	58	30	53	80	94	94	122	142
Operating Profit Margin (%)	17.8%	24.7%	27.1%	16.6%	25.2%	28.9%	29.7%	32.6%	35.5%	34.7%
Other Income ⓘ +	1	1	2	3	1	1	3	4	4	9
Exceptional Items ⓘ	0	0	0	0	0	-1	0	0	0	-2
Interest ⓘ	2	5	5	4	2	1	3	2	2	1
Depreciation ⓘ	10	16	20	21	23	23	31	33	35	44
Profit Before Tax ⓘ	17	26	35	8	28	55	64	63	89	104
Tax ⓘ	6	9	10	1	7	14	17	14	22	26
Profit After Tax	11	16	25	7	21	41	47	49	67	78
PAT Margin (%)	6.9%	9.0%	11.9%	3.8%	10.2%	14.9%	15.0%	16.9%	19.4%	19.0%
Adjusted EPS (₹)	2.4	3.7	5.7	1.6	4.8	9.3	10.7	11.0	15.0	17.4
Dividend Payout Ratio (%)	0%	26.90%	17.50%	0%	20.80%	10.80%	9.40%	9.10%	6.70%	11.50%

Valuation of Vimta Labs - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	136	152	172	173	194	231	274	307	372	450
Share Capital ⓘ	4	4	4	4	4	4	4	4	4	9
Reserves ⓘ	132	148	167	169	190	226	270	303	368	441
Debt +	37	33	17	22	22	13	10	14	3	2
Long Term Debt	18	19	12	5	14	13	10	9	3	2
Short Term Debt	19	13	5	18	8	0	0	5	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	15	13	11	10	15	12	14	8	10	12
Others Liabilities ⓘ	33	35	38	39	41	49	58	57	75	93
Total Liabilities ⓘ	222	232	237	244	272	304	356	387	460	556
Fixed Assets
Net Fixed Assets ⓘ +	88	140	135	131	128	162	168	166	230	305
Gross Block	98	166	180	197	216	266	300	331	427	544
Accumulated Depreciation	10	25	45	66	88	105	133	166	197	239
CWIP ⓘ	53	0	4	2	17	0	12	59	38	18
Investments ⓘ	0	0	0	6	6	6	6	0	0	2
Inventories	15	18	19	17	15	17	23	25	25	30
Trade Receivables	42	56	59	58	73	77	80	87	106	106
Cash Equivalents	1	3	3	7	7	11	39	26	33	65
Others Assets ⓘ	22	15	18	24	26	30	28	25	28	30
Total Assets ⓘ	222	232	237	244	272	304	356	387	460	556

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	24	33	39	24	37	59	87	61	94	147
PBT ⓘ	17	26	35	8	28	55	64	54	90	104
Adjustment ⓘ	12	23	30	23	29	31	39	37	34	51
Changes in Working Capital ⓘ	1	-9	-16	-1	-13	-11	-4	-15	-8	16
Tax Paid ⓘ	-5	-6	-10	-6	-7	-17	-12	-15	-22	-24
Cash Flow From Investing Activity ⓘ +	-39	-24	-16	-20	-32	-38	-57	-76	-76	-130
Capex	-40	-24	-16	-14	-32	-39	-50	-74	-77	-100
Net Investments	-0	0	-0	-0	1	-0	-9	-3	-5	-32
Others ⓘ	0	1	1	-6	0	1	1	2	6	2
Cash Flow From Financing Activity ⓘ +	13	-8	-23	-1	-5	-16	-11	-2	-16	-10
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	8	2	-7	-6	7	-3	-5	-1	-5	-5
Interest Paid ⓘ	-2	-4	-3	-2	-2	-1	-1	-1	-1	-1
Dividend Paid ⓘ	-3	0	-5	-5	0	-4	-4	-4	-4	-4
Others ⓘ	9	-6	-8	12	-9	-8	-0	5	-5	-0
Net Cash Flow ⓘ	-2	1	1	3	1	5	19	-17	2	7

Financial Ratio

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	8.08	11.4	15.64	4.02	11.58	19.32	18.73	16.78	19.65	18.87
ROCE (%)	11.22	16.55	20.42	6.01	14.24	23.85	24.25	20.55	25.23	24.81
Asset Turnover Ratio	0.77	0.81	0.91	0.75	0.81	0.96	0.95	0.78	0.81	0.8
PAT to CFO Conversion(x)	2.18	2.06	1.56	3.43	1.76	1.44	1.85	1.24	1.4	1.88
Working Capital Days
Receivable Days	95	97.80	98.20	117.40	114.30	99.30	90.80	105.50	102.50	95
Inventory Days	37.10	33.30	32	36.50	27.70	21.20	23.20	29.90	26.40	24.70
Payable Days	0	2,187.20	-5,631	0	1,516.60	0	0	0	0	0

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vimta Labs Ltd FAQs

The current trading price of Vimta Labs on 05-Jun-2026 10:31 is ₹513.0.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Vimta Labs stood at ₹2,285.7 Cr

The latest P/E ratio of Vimta Labs as of 04-Jun-2026 is 29.49.

The latest P/B ratio of Vimta Labs as of 04-Jun-2026 is 5.08.

The 52-week high of Vimta Labs is ₹902.9 and the 52-week low is ₹377.3.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vimta Labs is ₹407 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Vimta Labs Ltd is a good quality company.

The key valuation ratios of Vimta Labs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Vimta Labs Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Vimta Labs Ltd

Vimta Labs is Indiaâ€™s leading contract research and testing organization. Established in 1984, Vimta has an envious track record of serving several market leaders across the globe.

Vimta supports regulatory authorities in mandatory certification of food and agri products exported from India. Vimta assists the food industry commissions for nutritional labelling, food safety evaluations, trace analysis and shelf life studies.

Vimta has a team of 684 professionals comprising 446 scientists in various disciplines such as chemistry, pharma, medicine, microbiology, molecular biology and informatics. The team is slated to double in next three years.

Vimta is a multi-site organization with more than 300,000 sqft world class laboratory facilities. The technologies deployed at Vimta are current and leading edge, duly validated.

Vimta has over 12 years of experience in providing preclinical services to Pharma companies world-wide accordance with the guidelines prescribed by international agencies.

Vimta has a state-of-art building of Class 10,000 Pre-clinical facility with a total built up area of 33,000 sq.ft. with 32 rodent experimental rooms, 5 procedure rooms, separate quarantine facility and distinct non-rodent facility with 48 SS kennels with a comfortable perch, liberal exercise area.

It provides services in pharmacology, toxicology and DMPK areas. The toxicology services include but not limited to in-vivo and in-vitro genotoxicity, acute to chronic toxicity, carcinogenicity, reproductive toxicity studies, safety pharmacology, and immunotoxicology. Pharmacology services are available in various therapeutics areas such as pain & inflammation, metabolic disorders, respiratory, CNS, and xenograft & allograft models for oncology. In addition to the regulatory studies we use tailor-made in vitro and in vivo ADME techniques to help profile your drug candidate in both rodent and non-rodent animals models.

Services offered by the company:

Advanced Molecular Biology
Food and Agriculture
Drugs & Pharma
Water
Environmental Assessments
Clinical Research
Clinical Reference Lab Services
Preclinical Research
Genomics Online Ordering

Achievements/ recognition

NABL as per ISO 15189:2007

Vimta Labs Ltd (VIMTALABS)

Vimta Labs Ltd (VIMTALABS)

Vimta Labs stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Vimta Labs - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vimta Labs Ltd FAQs

About Vimta Labs Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Vimta Labs Ltd (VIMTALABS)

Vimta Labs Ltd (VIMTALABS)

Vimta Labs stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Vimta Labs - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vimta Labs Ltd FAQs

What is the share price of Vimta Labs?

What is the market cap of Vimta Labs?

What is the P/E ratio of Vimta Labs?

What is the P/B ratio of Vimta Labs?

What is the 52-week high and low of Vimta Labs?

What is the TTM revenue of Vimta Labs?

Is Vimta Labs Ltd a good quality company?

Is Vimta Labs Ltd undervalued or overvalued?

Is Vimta Labs Ltd a good buy now?

About Vimta Labs Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.